Universal CAR-T therapy aims to tame autoimmune diseases
NCT ID NCT07203404
First seen Oct 31, 2025 · Last updated May 11, 2026 · Updated 26 times
Summary
This early-stage study tests a new treatment called RD06-05, which uses specially engineered immune cells to target and calm overactive immune responses in people with autoimmune diseases like lupus, vasculitis, and scleroderma. Up to 84 adults aged 18 to 75 will receive the therapy to see if it is safe and tolerable. The main goal is to check for side effects, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bioheng Study site
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.